Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report

Cabozantinib has been shown to have potent anti-ROS1 activity in many solid malignancies, particularly against those with solvent-front resistance mutations following crizotinib therapy. With regard to the most common CD74-ROS1 fusion, the efficacy of cabozantinib has only been demonstrated in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, Gao, Jinqi, Lv, Jinyan, Chen, Xi, Wu, Jinyu, Wang, Ruoyu, Jiang, Jianing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023875/
https://www.ncbi.nlm.nih.gov/pubmed/32103985
http://dx.doi.org/10.2147/OTT.S234733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023875/
https://www.ncbi.nlm.nih.gov/pubmed/32103985
http://dx.doi.org/10.2147/OTT.S234733

Ejemplares similares